Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report

Oliver Gautschi, MD; Joachim Diebold, MD

JTO Clinical and Research Reports (Apr 2021)

Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report

Oliver Gautschi, MD,
Joachim Diebold, MD

Affiliations

Oliver Gautschi, MD: Corresponding author. Address for correspondence: Oliver Gautschi, MD, Department of Oncology, Cantonal Hospital Lucerne, Lucerne, Switzerland.; Cantonal Hospital Lucerne, Cancer Center, Lucerne, Switzerland
Joachim Diebold, MD: Cantonal Hospital Lucerne, Cancer Center, Lucerne, Switzerland

Journal volume & issue: Vol. 2, no. 4
p. 100162

Abstract

Read online

We previously published in the Journal of Thoracic Oncology the case of a patient with EGFR and MET-driven lung cancer and extracranial response to capmatinib and osimertinib. Here, we report on a second patient treated with the same combination, revealing complete and durable intracranial response. Adding capmatinib to osimertinib seems to be an effective salvage therapy for patients with EGFR-mutant lung cancer and acquired MET amplification.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords